As class action lawsuits go, I have never encountered one any more questionable than the recent complaint issued against Medivation Inc. (MDVN), via the law firm Izard Nobel LLP.

Readers of this space may recall that just a few days ago I decried the sell off of shares that occurred on the heels of Medivation's ill-fated phase 3 drug trial of the potential Alzheimer's treatment dimebon. At that time, I pointed out that one failed drug trial is not equal to the failure of a company. I still stand by that common sense determination.

Continue reading Medivation Class Action Has Questionable Roots

Medivation Class Action Has Questionable Roots originally appeared on BloggingStocks on Wed, 10 Mar 2010 12:40:00 EST. Please see our terms for use of feeds.

I really wish I had several thousand dollars to play with right about now. If I did, I'd plunk the entire wad down on Medivation (MDVN) and let it ride.

Why would I do that? My reasoning is simple. I'd do that because the recent sell-off of Medivation, on the heels of a disappointing phase 3 study of the drug dimebon (latrepirdine) absolutely blew the floor out from under the company's shares. I'm telling you right now, I believe that sell-off has gone twice as deep as good sense can justify. At least, that's the way I see it.

Continue reading What's Up with Medivation?

What's Up with Medivation? originally appeared on BloggingStocks on Sat, 06 Mar 2010 14:10:00 EST. Please see our terms for use of feeds.

Continue reading Closing Bell: When Bad Jobs Are Really Great

Closing Bell: When Bad Jobs Are Really Great originally appeared on BloggingStocks on Fri, 05 Mar 2010 16:30:00 EST. Please see our terms for use of feeds.

For speculative investors aware of the risks associated with a development stage drug company, Karim Rahemtulla looks to Medivation (NASDAQ: MDVN), a play on development of a drug to treat Alzheimer's.

In his Xcelerated Profits Report, the advisor explains, "Medivation continues to make good clinical trial progress with its Dimebon drug for Alzheimer's Disease.

"The firm received some mainstream media attention at the recent International Conference on Alzheimer's Disease (ICAD) in Vienna. Reuters, Forbes and Bloomberg all reported that Dimebon is changing the way scientists think about Alzheimer's.

Continue reading Medivation (MDVN): Drug firm targets Alzheimer's

Medivation (MDVN): Drug firm targets Alzheimer's originally appeared on BloggingStocks on Mon, 14 Sep 2009 10:30:00 EST. Please see our terms for use of feeds.

• Apple Inc (NASDAQ: AAPL) Worldwide Developers Conference to be held from June 11 through June 15.
• Texas Instruments Incorporated (NYSE: TXN) mid-quarter update conference call to be held at 5pm.
• Medivation Inc (NASDAQ: MDVN) to discuss Phase II study results for Dimebon for Alzheimer's.

• Lehman Brothers Holdings Inc (NYSE: LEH) to report Q2 earnings; conference call at 10am.

• FDA Endocrinologic and Metabolic Drugs Advisory Committee Meeting on Sanofi-Aventis's (NYSE: SNY) Acomplia at 8am.

• The Goldman Sachs Group Inc (NYSE: GS) to report Q2 earnings; conference call at 11am.
• Adobe Systems Incorporated (NASDAQ: ADBE) to report Q2 earnings.
• Telkonet Inc (AMEX: TKO) to hold conference call at 11am to provide business update.

• PDUFA date for Encysive Pharmaceuticals Inc's (NASDAQ: ENCY) Thelin for Pulmonary Arterial Hypertension (PAH).

Market highlights for next week: Apple Worldwide Developers Conference originally appeared on BloggingStocks on Fri, 08 Jun 2007 16:00:00 EST. Please see our terms for use of feeds.

MOST NOTEWORTHY:

• JP Morgan started Nintendo Ltd (OTC: NTDOY) with an Overweight rating.
• Lazard initiated shares of FuelCell Energy (NASDAQ: FCEL) with a Buy rating and $11 target, as the firm believes the company has the best bookings prospects in its history.

• Discovery Holding Co (NASDAQ: DISCA) was initiated at Pali Research with a Buy rating and $25.50 target. Pali said Discovery now appears committed to developing unique,"on-brand" proprietary content across all its cable networks that it can exploit through an increasing number of distribution platforms; Pali added that this is a company that no longer feels compelled to be in every country around the globe.
• Pacific Crest initiated shares of Vocus, Inc (NASDAQ: VOCS) with an Outperform rating and $28 target, as the firm believes the company has a strong competitive position.
• Cowen initiated Medivation, Inc (NASDAQ: MDVN) with a Neutral rating based on valuation.

Analyst initiations 4-16-07: Nintendo started with an Overweight at JP Morgan originally appeared on BloggingStocks on Mon, 16 Apr 2007 10:52:00 EST. Please see our terms for use of feeds.